Guardant Health, Inc.

NASDAQ:GH

Medical - Diagnostics & Research

Healthcare
$145.14 +2.07%

+$2.67 today

Market cap
$19.64B
Beta
1.62
P/E (TTM)
-39.9
EPS (TTM)
-$3.30
52W Low $40.35High $135.00

Volume 1.50M

Average 2.21M

GH Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Guardant Health, Inc.NASDAQ: GH

Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares grows in line with its trailing trend

Q3 FY2026 weighted avg shares of 134.42M shares rose 7.7% year over year, ahead of the +6.0% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.8% from the prior quarter. Over 3 fiscal years it compounded at +7.1% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +7.7% holds above the trailing-twelve-month pace of +6.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
134.42M+1.8% QoQ
Last fiscal yearDec 2025
125.37M+2.1% YoY
LTMSep 2026
131.61M+6.0% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.7%——
1 year+2.1%——
3-year CAGR+7.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
125.37M USD
Year-over-year change
+2.1%
4-year CAGR
+5.5%

Weighted Avg Shares vs competitors

How GH compares with its peers on the latest reported figures

  • GH's LTM Sep 2026 weighted avg shares of 131.61M shares is the 2nd highest of the 10 companies compared; the peer median is 45.72M shares.
  • Its year-over-year change of +6.0% is the 5th highest of 10, against a peer median of +2.4%.
  • Over three fiscal years its annual growth of +7.1% compares with a peer median of +5.4%.
GH Competitors Peer median
Weighted Avg Shares for GH and competitors
Company Period LTM YoY 3-year CAGR
NTRANatera, Inc.LTM Jun 2026139.67M +7.5%+11.6%
GHGuardant Health, Inc.LTM Sep 2026131.61M +6.0%+7.1%
NEONeoGenomics, Inc.LTM Jun 2026128.84M +1.3%+1.0%
PSNLPersonalis, Inc.LTM Mar 202693.42M +36.5%+25.0%
MYGNMyriad Genetics, Inc.LTM Mar 202693.15M +2.4%+5.0%
BLLNBillionToOne, Inc.LTM Jun 202645.72M +2.2%—
GRALGRAIL, Inc.LTM Jun 202640.15M +20.6%+5.8%
FLGTFulgent Genetics, Inc.LTM Mar 202630.81M +1.0%+0.7%
CSTLCastle Biosciences, Inc.LTM Mar 202628.3M +0.9%+3.6%
BDSXBiodesix, Inc.LTM Mar 20268.14M +14.9%+53.1%
Peer median (excluding GH) 45.72M+2.4%+5.4%

Competitors are the stored peer set for GH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue373.65M449.54M563.95M739.02M982.02M
Cost of Revenue122.91M156.33M227.05M289.8M349.01M
Gross Profit250.74M293.21M336.9M449.22M633.01M
Gross Margin67.1%65.2%59.7%60.8%64.5%
Research & Development263.22M373.81M367.19M347.75M364.19M
Selling, General & Admin398.52M463.78M451.03M545.06M706.07M
Operating Expenses661.74M837.59M901.62M892.81M1.07B
Depreciation & Amortization22.27M35.96M42.88M42.39M39.74M
EBITDA(359.62M)(614.91M)(433.31M)(390.12M)(373.91M)
EBITDA Margin-96.2%-136.8%-76.8%-52.8%-38.1%
Operating Income(411M)(544.38M)(564.73M)(443.59M)(437.25M)
Operating Margin-110.0%-121.1%-100.1%-60.0%-44.5%
Interest Income3.93M6.07M35.37M53.69M34.1M
Interest Expense2.58M2.58M2.58M2.58M3.9M
Other Income / Expenses26.53M(109.07M)85.96M8.51M19.71M
Income Before Tax(384.47M)(653.45M)(478.76M)(435.09M)(417.54M)
Pre-Tax Margin-102.9%-145.4%-84.9%-58.9%-42.5%
Income Tax Expense300K1.14M685K1.28M(1.26M)
Net Income(405.67M)(654.59M)(479.45M)(436.37M)(416.28M)
Net Margin-108.6%-145.6%-85.0%-59.0%-42.4%
EPS (Basic)(4.00)(6.41)(4.28)(3.56)(3.32)
EPS (Diluted)(4.00)(6.41)(4.28)(3.56)(3.32)
Weighted Avg Shares101.31M102.18M111.99M122.75M125.37M
Weighted Avg Shares (Diluted)101.31M102.18M111.99M122.75M125.37M

Guardant Health, Inc.

NASDAQ:GH

Intrinsic Alpha fair value

Locked

Current Price

$145.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.